Filling the void: digoxin and the first randomized evidence in rheumatic heart disease

The Digoxin in Rheumatic Heart Disease (Dig-RHD) trial marks an important shift in rheumatic heart disease by replacing long-standing therapeutic assumption with direct randomized evidence. In a condition affecting predominantly young patients in low- and middle- income countries, practice has often relied on extrapolation from non-valvular heart failure populations despite clear differences in disease biology, treatment access, and clinical context. By reducing heart failure events in symptomatic patients, Dig-RHD suggests that the value of digoxin in RHD may lie in preventing deterioration and preserving stability, rather than in mortality reduction alone. This distinction matters because worsening heart failure in RHD represents functional decline, recurrent healthcare use, and loss of clinical reserve in settings where advanced interventions may be delayed or unavailable. The findings support reassessment the role of digoxin in symptomatic RHD while underscoring the need to define optimal timing, rhythm-specific effects, disease severity, and background therapy. More broadly, Dig-RHD shows that rigorous outcome trials in RHD are feasible and necessary for a population still underrepresented in cardiovascular research.